Showing results (81-90 of 139) with videos related to
Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)Jean-François Delattre, Romain Cohen, Julie Henriques, et al.Journal of Cancer|May 22, 2014
ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant ChemotherapyAziz Zaanan, Cécile Dalban, Jean-François Emile, et al.BJU International|August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancerCharlotte Fenioux, Christophe Louvet, Emilie Charton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1Thierry André, Emmanuel Quinaux, Christophe Louvet, et al.Cellular Oncology (Dordrecht, Netherlands)|December 12, 2019
High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancerAziz Zaanan, Claire Calmel, Julie Henriques, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand, Andres Cervantes, Arie Figer, et al.British Journal of Cancer|July 13, 2016
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)Dewi Vernerey, Florence Huguet, Angélique Vienot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) studyRosine Guimbaud, Christophe Louvet, Pauline Ries, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 StudyBenoist Chibaudel, Frédérique Maindrault-Goebel, Gérard Lledo, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 TrialsEdouard Auclin, Julien Taieb, Come Lepage, et al.Pageof 14